GH
Guardant Health, Inc.
GH's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over GH overall, supported by stronger fundamentals and lower modeled downside.
GH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
GH's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
GH PE Valuation
GH has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
GH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect GH's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
GH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.69 | -$0.48 |
| Q2 2026 | -$3.50 | -$0.15 |
| Q1 2026 | -$3.40 | -$0.01 |
| Q4 2025 | -$3.32 | +$0.24 |
| Q3 2025 | -$3.21 | +$1.03 |
| Q2 2025 | -$3.35 | +$0.74 |
| Q1 2025 | -$3.39 | +$0.53 |
| Q4 2024 | -$3.56 | +$0.72 |
GH is still losing money, but less than at its worst: $3.69 per share over the past year, against $6.50 at its worst in early 2023.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over GH on earnings quality, reporting a profit while its opponent remains loss making.
GH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $361M | +36% |
| Q2 2026 | $335M | +44% |
| Q1 2026 | $301.7M | +48% |
| Q4 2025 | $281.3M | +39% |
| Q3 2025 | $265.2M | +39% |
| Q2 2025 | $232.1M | +31% |
| Q1 2025 | $203.5M | +21% |
| Q4 2024 | $201.8M | +30% |
GH's revenue has grown year over year every quarter since late 2020: $361M last quarter, up 36% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -37% | +0.5 points |
| Q2 2026 | -39% | +7.3 points |
| Q1 2026 | -40% | +14 points |
| Q4 2025 | -43% | +20 points |
| Q3 2025 | -37% | +24 points |
| Q2 2025 | -46% | +11 points |
| Q1 2025 | -55% | +4.6 points |
| Q4 2024 | -62% | +65 points |
GH's operating margin was −37% last quarter, up 0.5 points from the same quarter a year ago, near the top of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over GH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over GH on profitability, with a higher operating margin.
GH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$37.2M | +$8.6M |
| Q2 2026 | -$69.5M | -$3.6M |
| Q1 2026 | -$71.2M | -$4.1M |
| Q4 2025 | -$54.2M | +$29.2M |
| Q3 2025 | -$45.8M | +$9.5M |
| Q2 2025 | -$65.9M | +$33.1M |
| Q1 2025 | -$67.1M | -$29.9M |
| Q4 2024 | -$83.4M | -$583K |
GH has burned cash in almost every quarter: −$232M over the past year, against −$262M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over GH on cash generation, producing positive trailing cash flow while its opponent burns cash.
GH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.6M shares |
| 1 year | +7.7% | +9.6M shares |
| 3 years | +14% | +16.7M shares |
| 5 years | +33% | +33M shares |
| Available history | +48% | +43.8M shares |
GH has 134M diluted shares, up 7.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $45M |
| Q4 2019 | — |
GH hasn't bought back shares in the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over GH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
GH Net Leverage
GH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
GH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.5 | Neutral |
| Stochastic | 45.3 | Neutral |
GH's weekly RSI is 52 (neutral) and its Stochastic is 45 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
GH PE vs Healthcare Sector
GH has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
GH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $166.8 | 7.2% below |
| 20 week MA | $164.2 | 5.7% below |
| 50 week MA | $128.2 | 21% above |
| 100 week MA | $90.8 | 71% above |
| 200 week MA | $59.1 | 162% above |
GH has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 162% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over GH on trend strength, trading above more of its moving averages.
GH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $78.8 | $133.8 | +70% |
| 2021 | $133.8 | $97.5 | -27% |
| 2022 | $97.5 | $27.9 | -71% |
| 2023 | $27.9 | $27.1 | -3% |
| 2024 | $27.1 | $30.4 | +13% |
| 2025 | $30.4 | $103.0 | +238% |
| 2026 YTD | $103.0 | $154.9 | +50% |
GH has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.